Healthcare Industry News:  hemodialysis 

Devices

 News Release - May 1, 2006

NxStage(R) Medical Achieves Milestone with 500 Patients on Therapy

LAWRENCE, Mass., May 1 (HSMN NewsFeed) -- NxStage Medical, Inc. (Nasdaq: NXTM ) -- announced today that during the month of April 2006 it surpassed the milestone of 500 patients on home hemodialysis therapy using its System One.

"We are extremely pleased to announce the achievement of this important milestone. The System One is gaining recognition as a highly-effective, more convenient therapy for patients suffering from end-stage renal disease (ESRD) which is leading to our growing traction in the chronic market. We are aggressively pursuing our goal of becoming the market leader in home hemodialysis and are confident that we will achieve 1,000 patients on therapy during the fourth quarter of this year," stated Mr. Jeff Burbank, President and Chief Executive Officer.

"We congratulate NxStage on reaching this milestone, and for the boost that their efforts have given to home dialysis in general," said Dr. John Moran, Chief Medical Officer for Wellbound, a home dialysis-focused provider based in Mountain View, California. "Home daily dialysis is a tremendous option for patients, and one from which many more could benefit. At Wellbound our patients now have more than 55 patient-years' experience with the NxStage technology. We were thrilled to recently celebrate with our first eight patients their second anniversary on NxStage therapy. I look forward to seeing not 500, not 5,000, but more than 50,000 patients worldwide on home hemodialysis therapies," added Dr. Moran.

About NxStage Medical:

NxStage Medical, Inc. (Nasdaq: NXTM ) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative dialysis systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

About End-Stage Renal Disease:

End-stage renal disease is the permanent failure of the kidneys to filter the body's wastes. It is most commonly caused by diabetes, hypertension, or genetic disorders. In order to survive, ESRD patients must use some form of therapy to replace the function of the kidneys for the rest of their lives. Currently, over 450,000 patients in the United States suffer from ESRD, and the costs of treating ESRD patients are more than $20 billion annually in the U.S. Due to increases in diabetes, hypertension, and the aging of the U.S. population, those figures are projected to double within the next 10-15 years. The most common form of kidney replacement therapy in the United States today is hemodialysis, which is used by over 350,000 patients currently. The great majority of these patients are treated with conventional, in-center hemodialysis, in which they must travel to a nearby dialysis center three times per week, where they are connected to dialysis machines for treatments lasting approximately three to four hours, to cleanse their blood.

About hemodialysis:

Today, most patients undergo hemodialysis therapy three times a week in outpatient dialysis centers. This differs significantly from the 24/7 workings of the naturally functioning kidney. Increasingly, clinicians and patients have recognized opportunities for therapy improvements with more frequent, or daily, dialysis. More than a hundred clinical papers have reported on the health and quality of life benefits of hemodialysis done more frequently. The reported benefits include reduced hypertension, reduced cardiac strain and left ventricular hypertrophy, reduced amyloid disease, and improved anemia status, appetite, and quality of life, including the ability to return to work. A summary of the literature discussing these benefits can be found on NxStage's website, http://www.nxstage.com.

Forward-Looking Statements:

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Examples of these forward-looking statements include statements as to the growth of the ESRD patient population, the anticipated demand for home dialysis products, the anticipated market acceptance and demand for NxStage's products, including expectations regarding patient count during 2006. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond NxStage's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance or achievements including growth in home or more frequent hemodialysis, market acceptance and demand for NxStage's System One, and certain other factors that may affect future operating results and which are detailed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2005.

In addition, the statements in this press release represent NxStage's expectations and beliefs as of the date of this press release. NxStage anticipates that subsequent events and developments may cause these expectations and beliefs to change. However, while NxStage may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events, or otherwise. These forward-looking statements should not be relied upon as representing NxStage's expectations or beliefs as of any date subsequent to the date of this press release.


Source: NxStage Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.